We previously reported that treatment of Fischer-344 rats with 2-amino-4,5-diphenylthiazole (DPT) results in renal cystic changes. The present study was undertaken to examine the effects of long-term DPT treatment after initiation of kidney carcinogenesis with N -ethyl-N -hydroxyethylnitrosoamine (EHEN) in Wistar rats. One hundred forty-four 6-wk-old male Wistar rats were divided into 6 equal receiving groups: 1000 ppm EHEN or normal tap water for 2 wk followed by 1.06% DPT or basal diet for the subsequent 14 or 30 wk. Controls were maintained without treatment throughout. Subgroups of 6 animals from each group were sacrificed after 8, 16, 24, and 32 wk for histopathological assessment of lesion development in the kidneys and liver. Animals treated with DPT first developed cystic changes of the kidneys (primarily at the corticomedullary border) after 8 wk of treatment, and these changes progressed with time thereafter. In the groups in which DPT treatment was discontinued after 14 wk, cysts then gradually decreased in size. All tumors detected in the kidneys were histopathologically diagnosed as renal cell adenomas. The tumor multiplicity after 32 wk of treatment was significantly higher in Group I, receiving EHEN + DPT for 30 wk (6.33 & p l u s m n ; 4.46), and Group III, receiving EHEN + DPT for 14 wk (3.83 &plusmn; 1.57), than in Group V, EHEN alone (1.00 &plusmn; 0.58) (p < 0.05). Renal cell tumors within cysts were only seen in Groups I and III. The general bromodeoxyuridine labeling indices for the kidneys at week 32 were significantly higher in Group I (55.94 &plusmn; 21.08 cells/mm 2 ) and Group III (53.75 &plusmn; 12.38 cells/mm2) than in Group V (22.38 &plusmn; 6.98 cells/mm2) (p < 0.05). In conclusion, DPT caused cystic changes in rat kidneys, which, however, gradually decreased in size after the treatment was discontinued, suggesting a reversible nature. DPT clearly also promotes renal tumor development after EHEN initiation, and this effect persists, to a certain extent, even after the insult is removed.
INTRODUCTION
It is well known that treatment of rats with 2-amino-4,5-diphenylthiazole (DPT) leads to the development of renal cysts resembling those observed with acquired cystic disease of the human kidney (ACDK) (4) . Although the detailed mechanisms responsible for ACDK and the progressive renal dysfunction due to the growth of cystic lesions remain unknown, rats with DPT-induced cystic kidneys are often used as an experimental model of ACDK.
DPT induces 2 different types of progressive tubular changes: cystic transformation and hyperplastic/atrophic tubular changes (3) . The first occur in the collecting tubules of the outer medulla and cortex and slowly increase after their initial appearance at about 8 wk. Hyperplastic/ atrophic changes involve between 25 and 50% of tubular profiles, in a distinct cluster in the cortex, after approximately 12 wk of drug treatment. In DPT-treated rats, basement membranes lining cysts were thickened severalfold and exhibited extensive loss and disorder of ruthe-nium red binding sites, indicating loss of sulfated proteoglycans (2) . We previously reported that Fischer-344 rats treated with DPT could serve as an experimental model, not only for cystic changes in the kidneys but also for promotion of renal carcinogenesis in rats initiated with N-ethyl-Nhydroxyethylnitrosamine (EHEN) , which selectively induced tumors of the renal proximal tubular epithelium (20) . However, the yield of renal tumors was low in contrast to the hepatocellular tumors observed in all animals at the end of the study. We therefore repeated the same protocol in Wistar rats (a strain of rat often used in experimental renal carcinogenesis) and included an assessment of cell proliferation activity following DPT treatment, using immunohistochemical demonstration of bromodeoxyuridine (BrdU) incorporation.
MATERIALS AND METHODS
Experimental Animals. One hundred forty-four male Wistar rats (Crj: Wistar) were purchased at 6 wk of age from Charles River Japan, Inc. (Hino, Japan) and housed in plastic cages (3 rats per cage) in an air-conditioned room at 22 ± 2°C and a humidity of 50% with a 12-hr light/dark cycle. They were weighed every week and fed on standard Oriental MF diet (Oriental Yeast Co., Tokyo), except during the drug treatment period, and allowed free access to tap water throughout.
Test Chemicals. DPT (Travenol Lab. Inc., Deerfield, Illinois, USA) was administered in chow pellets at 1.06%. EHEN (Nacarai Tesque Inc., Kyoto, Japan) was administered in the form of a 1,000-ppm solution in tap water.
Experimental Design. In Group I, 24 rats were treated with DPT for 30 wk after a 2-wk 1,000-ppm EHEN treatment. In Group II, 24 rats were treated with DPT for 30 wk after basal diet for 2 wk. In Group III, 24 rats were treated with DPT for 14 wk after a 2-wk 1,000-ppm EHEN treatment. In Group IV, 24 rats were treated with DPT for 14 wk after basal diet for 2 wk. In Group V, 24 rats were given basal diet for 30 wk after a 2-wk 1,000-ppm EHEN treatment. In Group VI, 24 rats were given basal diet for 32 wk (Fig. 1 ). At weeks 8, 16, 24, and 32 after the start of the experiment, subgroups of 6 rats from each of the groups were sacrificed after urine and blood samples had been taken for biochemical tests (blood urea nitrogen [BUN] , creatinine, and osmotic pressure of urine). BrdU (Sigma Chemical Co., St. Louis, MO) was injected intraperitoneally at 2 mg/100 g body weight into 3 rats of each group 1 hr before death. All kidneys and livers were macroscopically examined for abnormalities and then weighed. In the groups injected with BrdU slices were fixed in 70% ethanol and in the other groups in 10% formalin for routine processing and embedding in paraffin, sectioned, and stained with hematoxylin and eosin for histolopathogical assessment of preneoplastic and neoplastic lesion development and immunohistochemical demonstration of BrdU in corporation using the avidin-biotin method (ABC kits; Burlingame, CA). Deparafinized sections were rinsed with distilled water, hydrolyzed with 4 N HCI for 20 min at 37°C, and rinsed with borate buffer at pH 7.6. Denatured sections were treated with 0.01 % trypsin for 3 min at 37°C.
Mouse monoclonal anti-BrdU antibody (Becton Dickinson, Rochelle Park, NJ) was used at a dilution of 1:50 for 1 hr. The chromogen was 3,3'-diaminobenzidine tetrahydrochloride as 0.05% solution with 0.01% hydrogen peroxide. Sections were counterstained with Mayer's hematoxylin for microscopic examination. BrdU-labeled tubular cells per square millimeter were counted histochemically in 10 randomly selected areas with and without preneoplastic and neoplastic lesions in the renal cortex in each kidney. Quantitative data were analyzed for statistical significance with the Student's t-test for frequency and the Fisher's exact test for incidence.
RESULTS

Changes in Body and Kidney Weights
Body weight curves are shown in Fig. 2 . EHEN treatment was associated with body weight decrease at week 1, but this was less apparent at week 2. At week 32, there was no significant intergroup differences in body weight. DPT treatment caused a significant increase in kidney weight from week 8 onward, but this proved reversible after the DPT was discontinued at week 14. From week 8 to 32, the relative kidney weight for Groups I and II (treated with DPT for 30 wk) was significantly higher than that for Group V (treated with EHEN alone) and Group VI (untreated controls). The relative kidney weight at week 32 for Groups III and IV (groups where DPT was discontinued at week 14) did not differ significantly from that of Group V The relative kidney weights did not differ significantly at any time point between Group V and Group VI (Fig. 3 ).
Parameters o, f Renal Function
During weeks 8-32, the urine-concentrating ability of the kidneys of animals (treated with DPT) was significantly decreased (Fig. 4 ). This proved reversible after DPT was discontinued.
DPT treatment was associated with an increase in BUN and creatinine values, with a return to normal being apparent after discontinuation of the treatment (Figs. 5 and 6).
Macroscopic and Histopathological Features of Kidneys
Macroscopically, the kidneys of DPT-treated rats were markedly swollen at week 8 as compared to those of untreated controls, with markedly irregular surfaces and cyst formation in cut sections. The same changes were more pronounced at week 16 and at week 32; 5 milky-white, irregularly demarcated tumors were seen (3 in Group I and 1 each in Groups III and V), typical examples being illustrated in Fig. 7 .
When examined histologically, all DTP-treated rats showed tubular dilation (primarily dilation of the tubular cortex) at week 8 and subsequent weeks. At week 16, stromal fibrosis was observed, accompanied by marked cyst formation. In Groups III and IV, where DPT was discontinued in week 14, cysts demonstrated a progressive decrease in size at weeks 24 and 32. In Groups I and II, receiving DPT continuously, dilative changes had spread from the distal portion of the nephron to the proximal, and most nephrons had been occupied by cysts by week 32 (Fig.  8 ). Cystic hyperplasia was never seen in any rat without DPT treatment. Simple hyperplasias presented as small, single or multiple tubular structures characterized by increased basophilia (Fig. 9 ). Cystic hyperplasias were simple hyperplastic lesions demonstrating cyst formation. Adenomatous hyperplasias consisted of basophilic cells with abundant cytoplasm-like tumor cells, the normal tubular morphology being lost. A diagnosis of adenomatous hyperplasia ( Fig. 10 ) was made for lesions less than 3 times the size of a glo- merulus. Larger lesions were classified as renal tubular cell adenomas (Fig. 11 ). Such lesions were occasionally observed within cysts (Fig. 12 ).
In DPT-treated rats, simple hyperplasia was first detected no. 4.-Urine-concentratW g ability ot the kidneys ot rats treated with EHEN and DPT: 0 = Group I (EHEN 2 wk + DPT 30 wk); . = Group II (basal diet 2 wk + DPT 30 wk); A = Group III (EHEN 2 wk + DPT 14 wk); A = Group IV (basal diet 2 wk + DPT 14 wk); = Group V (EHEN 2 wk + basal diet 30 wk); N = Group VI (untreated controls). aSignificantly different (p < 0.05) from Group VI in week 32. hSignificantly different (p < 0.05) from Group V in week 32. at week 8. In rats treated with EHEN alone and untreated controls, it was first detected in week 16. In Groups I and III , the prevalence of adenomatous hyperplasia increased gradually after week 16 and reached 100% in week 32. In Groups II, IV, and V, about half of the animals had adenomatous hyperplasia when examined in week 24 and subsequent weeks.
The quantitative data for renal cystic lesions, hyperplasias, and tumors are summarized in Table I. The average number of adenomatous hyperplasias per animal at week 32 was significantly higher for Groups I and III (treated with both EHEN and DPT) than for Group V (treated with EHEN alone) and Group VI (untreated controls). The average number of renal cell tumors per animal in week 32 was also significantly higher for Groups I and III than for Groups V and VI. The average number of renal cell tumors within cysts in week 32 was significantly higher for Groups I and III than for Groups V and VI (Table II) . No neoplastic lesions were observed in the kidneys of rats not receiving EHEN.
Macroscopic and Histophathological Features of Livers
Macroscopic observation revealed the surfaces of all livers to be smooth. Histopathologically, hyperplastic nodules were seen in 2 (33.3%) of 6 rats of Group I at week 32. Hepatocellular tumors were not observed in any of the groups.
BrdU Labeling Indices
The mean numbers of BrdU-labeled cells with or without adenomatous hyperplasia and adenomas in the kidneys of each group are shown in Table III . Numbers of BrdU-la- beled cells per square millimeter in randomly selected areas containing adenomatous hyperplasia and adenomas in the renal cortex of 4 sagittal renal sections in Groups I-V were all significantly higher than that in Group VI. Those in Groups I and III were significantly higher than in Group V. The mean numbers of BrdU-labeled cells in randomly selected cortical areas without hyperplasias and renal cell tu- 
DISCUSSION
In 1977, Dunnill et al (7) reported ACDK in the atrophic kidneys of some patients on long-term hemodialysis, noting that it often was complicated by development of adenomas or renal cell carcinomas. Subsequently, ACDK has been highlighted as a significant clinical problem. Although the exact mechanisms responsible for the disease remain unknown, Chung-Park et al (5) pressed immune response in the uremic state, (d) local factors, such as repeated infection or trauma of the urinary tract, and (e) tubular obstruction and accelerated arteriosclerosis. Kikuchi (13) observed a number of oxalate crystals in atypical epithelia as well as renal cancers and suggested that they might also be involved in the formation of lesions.
Chemicals that have been used to induce ACDK in experimental animals in reported studies include DPT, corticosteroid, adenine, nordihydroguaiaretic acid, diphenylamine, and phenol II (8-10, 17 ). On the basis of studies of these animal models of ACDK, primarily in rats, several views have been proposed to explain the observed tubular dilation: These include (a) mechanical obstruction of the collecting tubule at a point near the papilla due to epithelial cell proliferation, (b) elevated compliance of the basal membrane of the tubule, (c) release of Na-H20 into the tubule via the Na pump due to abnormal activity of Na-K adenosine triphosphatase, and (d) urinary tract infection. None of these alternatives, however, has gained wide acceptance as yet.
DPT is a thiazole derivative used as a dye additive for drugs and foods. Carone et al (4) first reported that its administration to Sprague-Dawley rats rapidly resulted in the development of cystic changes of their kidneys and that this change appeared irreversible after an exposure period of more than 12 wk. Chemicals reported to induce renal cell tumors include EHEN, N-nitrosomorphorine, N-4-(4-fluorobiphenyl)acetamine, lead acetate, and streptozotocin (1, 6, 11, 12, 16) . Regarding the carcinogenicity of the genotoxic agent EHEN, Druckrey et al (6) reported in 1964 that oral dosing resulted in renal epithelial tumors, hepatomas, and ovarian tumors. More recently, Hiasa et al (11) reported a model whereby EHEN selectively induced tumors of the renal tubular epithelium. Several nephrotoxic compounds, such as unleaded gasoline, have the ability to induce degenerative nephropathies linked to increased incidences of renal adenomas and carcinomas in the rat (18) . A considerable amount of data has thus accumulated on the relationship between nephrotoxicity and nephrocarcinogenicity. It has become evident that toxic lesions both precede and develop concurrently with tumorigenesis (15) . One mechanism proposed is that of cellular degeneration and death caused by toxic insult, resulting in increased proliferation or hyperplasia due to regeneration. This response may increase the chance of expression of indigenously or exogenously induced mutations in the proliferating cell population, which leads to tumor formation. Konishi et al (14) have reported that potassium dibasic phosphate and sodium phosphate are good promoters of EHEN-initiated kidney neoplasias in the rat.
In the present study, treatment of rats with DPT reduced the urine-concentrating ability of the kidney and elevated BUN and creatinine but this proved reversible at least after 14 wk of exposure. The results are therefore not in line with the conclusion of Carone et al (4) that changes caused by treatment with DPT for more than 12 wk are irreversible.
No investigators have reported any genotoxicity of DPT itself and, in the present case, no renal cell tumors developed in any rat treated with DTP alone although clear promotion of renal carcinogenesis was observed often EHEN initiation. However, DPT treatment alone following basal diet in the Group II and IV animals resulted in preneoplastic lesions. Our study is only 32 wk, when in our previous study DPT-treated kidneys were discontinued after week 48 (20) . DPT may be a carcinogen in the rat had this study been run longer.
The incidence of renal cell tumors did not differ significantly between any 2 of Groups I, III, and V; however, the tumor multiplicity in Groups I and III was significantly higher than that in Group V. The fact that the Group III value was midway between those for Group I and V despite only 14 wk of exposure indicates considerable persistence of the enhancing influence. The link with cyst development was well illustrated by the finding of renal cell tumors within cysts in Groups I and III
The BrdU labeling indices of kidneys in rats treated with both EHEN and DPT were very much higher than those for rats treated with either one of these agents alone. Renal cell tumors within cysts were seen in Groups I and III and not in Group V (treated with EHEN alone). These results seen in rats treated with both EHEN and DPT therefore seem to reflect interactions between EHEN and DPT.
In our previous study of Fischer-344 rats treated first with EHEN and then with DPT, only 3 rats developed renal cell tumors during the study period, whereas all rats developed hepatocellular tumors after week 48 (20) . In the present study, all Wistar rats treated with both EHEN and DPT had renal cell tumors at week 32, but none developed liver tumors. These results demonstrated that renal cell tumor incidence in Wistar rats was significantly higher than that in Fischer-344 rats.
Furthermore, at termination cystic tumorous lesions were in 5 of 6 rats treated with both EHEN and DPT, and the tumor multiplicity for these rats was as high as 3.67 ± 4.03. Tsuda et al (19) reported that of 20 Wistar rats treated with EHEN for 3 wk and then adenine for the subsequent 27 wk, 15 (75%) developed renal cell tumors. These results of past and present studies thus allow us to conclude that initial treatment of Wistar rats with EHEN and subsequent administration of agents causing cysts is a reliable approach for animal models of ACDK. To cast additional light on this problem, we are presently investigating the effects of DPT treatment prior to EHEN exposure.
